PARP1 and cancer: Thus, ATM mutations can act as an independent prognostic factor and a potential biomarker for immune checkpoint therapy in endometrial cancer.747 Moreover, ATM mutations are independently associated with longer OS in patients with metastatic CRC.748 ATM deficiency also renders cancer cells sensitive to topoisomerase I inhibitors or PARP inhibitors.